Skip to content
Home
Our Science
Therapeutic Areas
Team & Investors
Careers
News & Resources
Connect
News &
Resources
Featured Stories
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Read More
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Read More
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Read More
All-In Podcast
2023 All-In Summit – A discussion on the future of gene therapy
Read More
News
Patient Resources
Videos
All
Media Coverage
Press Releases
Press Releases
|
Posted on 11.1.23
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Read More
Media Coverage
|
Posted on 10.4.23
2023 All-In Summit – A discussion on the future of gene therapy
Read More
Media Coverage
|
Posted on 9.13.23
Webinar – The State of Biotech 2023
Read More
Media Coverage
|
Posted on 8.24.23
Developing universal AAV immuno-gene therapy for oncology
Read More
Media Coverage
|
Posted on 5.18.23
New biotech Siren calls for gene therapy and cancer to ‘get into the weeds together’
Read More
Media Coverage
|
Posted on 5.17.23
Siren emerges from stealth with plans to marry gene therapy to cancer immunotherapy
Read More
Media Coverage
|
Posted on 5.17.23
Nicole Paulk’s Siren Bio is building a gene therapy delivery vehicle against cancer
Read More
Media Coverage
|
Posted on 5.17.23
ASGCT News: Siren Biotechnology Hails Universal Gene Therapy for Oncology
Read More
Media Coverage
|
Posted on 5.17.23
A new startup looks to turn the workhorse of gene therapy against cancer
Read More
Press Releases
|
Posted on 5.17.23
Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy
Read More
1
2
3
4